Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)
Download: Excel (XLSX), Comma-separated (CSV)
Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | GR50 lower quartile | GR50 median | GR50 upper quartile | GRmax lower quartile | GRmax median | GRmax upper quartile | GRinf lower quartile | GRinf median | GRinf upper quartile | Hill Coefficient lower quartile | Hill Coefficient median | Hill Coefficient upper quartile | GR_AOC lower quartile | GR_AOC median | GR_AOC upper quartile | GEC50 lower quartile | GEC50 median | GEC50 upper quartile |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ribavirin | N/A | N/A | 100.0000 | 100.0000 | 100.0000 | 0.6045 | 0.7146 | 0.9546 | 0.4725 | 0.6701 | 0.9546 | 0.0000 | 0.0000 | 0.9838 | 0.0119 | 0.0416 | 0.0703 | 50.4745 | 100.0000 | 100.0000 | |
Triciribine | AKT | AKT | 0.1497 | 1.0069 | 10.2321 | -0.2208 | 0.0730 | 0.3595 | -0.6783 | -0.3270 | 0.0049 | 0.3693 | 0.5173 | 0.9769 | 0.1961 | 0.3180 | 0.4712 | 0.2958 | 1.3169 | 18.2553 | |
Omipalisib | PI3K | PI3K | 0.0049 | 0.0154 | 0.0397 | -0.8281 | -0.5752 | -0.4164 | -0.8004 | -0.5070 | -0.2908 | 0.6200 | 0.7592 | 0.9464 | 0.6332 | 0.8101 | 0.9689 | 0.0158 | 0.0370 | 0.0945 | |
Selumetinib | MEK | MAPK | 3.4703 | 100.0000 | 100.0000 | 0.2888 | 0.6993 | 0.8618 | 0.1384 | 0.6524 | 0.8687 | 0.0000 | 0.4990 | 0.9393 | 0.0510 | 0.1233 | 0.3040 | 0.3246 | 2.6951 | 100.0000 | |
PS-1145 | IKK | NFKB | 100.0000 | 100.0000 | 100.0000 | 0.8452 | 0.9304 | 0.9718 | 0.8353 | 0.9304 | 0.9695 | 0.0000 | 0.0000 | 0.8067 | -0.0033 | 0.0200 | 0.0533 | 100.0000 | 100.0000 | 100.0000 | |
Cetuximab | EGFR | ErbB | 100.0000 | 100.0000 | 100.0000 | 0.7284 | 0.8755 | 0.9754 | 0.5964 | 0.8555 | 0.9754 | 0.0000 | 0.0000 | 0.7916 | -0.0099 | 0.0234 | 0.0674 | 3.7461 | 100.0000 | 100.0000 | |
5-FU | TYMS | TYMS | 43.5628 | 98.8715 | 100.0000 | -0.6126 | -0.4736 | -0.0711 | -0.8532 | -0.6532 | -0.1200 | 0.5225 | 0.5967 | 0.7832 | 0.3295 | 0.4853 | 0.6100 | 100.0000 | 100.0000 | 100.0000 | |
PD 98059 | MEK | MAPK | 100.0000 | 100.0000 | 100.0000 | 0.5235 | 0.6650 | 0.8191 | -0.1517 | 0.5395 | 0.8149 | 0.0000 | 0.2473 | 0.7779 | 0.0463 | 0.0842 | 0.1501 | 32.4005 | 100.0000 | 100.0000 | |
Everolimus | MTOR | MTOR | 0.0432 | 0.6717 | 4.3873 | -0.8294 | -0.6714 | -0.2303 | -1.0000 | -1.0000 | -0.6838 | 0.2890 | 0.4230 | 0.7677 | 0.3295 | 0.4415 | 0.5925 | 1.5205 | 9.7227 | 26.2255 | |
Nilotinib | ABL | nRTK | 100.0000 | 100.0000 | 100.0000 | 0.7849 | 0.9109 | 1.0055 | 0.7841 | 0.9109 | 1.0055 | 0.0000 | 0.0000 | 0.7234 | 0.0029 | 0.0487 | 0.0775 | 73.6076 | 100.0000 | 100.0000 | |
5-DFUR | TYMS | TYMS | 68.5295 | 100.0000 | 100.0000 | -0.1871 | -0.0208 | 0.0399 | -0.5625 | -0.3158 | -0.1425 | 0.3943 | 0.5084 | 0.6195 | 0.2584 | 0.3100 | 0.3856 | 100.0000 | 100.0000 | 100.0000 | |
Torkinib | MTOR | MTOR | 0.0008 | 0.0021 | 0.0184 | -0.5713 | -0.3826 | -0.2014 | -0.6715 | -0.4047 | -0.1504 | 0.3324 | 0.3720 | 0.5454 | 0.6694 | 0.8411 | 1.0104 | 0.0046 | 0.0211 | 0.0646 | |
PD184352 | MEK | MAPK | 31.0822 | 100.0000 | 100.0000 | 0.4258 | 0.7584 | 0.9084 | -0.2272 | 0.7139 | 0.9084 | 0.0000 | 0.0524 | 0.4766 | 0.0368 | 0.0888 | 0.1432 | 63.7076 | 100.0000 | 100.0000 | |
Dichloroacetate | PDK | PDK | 100.0000 | 100.0000 | 100.0000 | 0.8082 | 0.8801 | 0.9216 | 0.7946 | 0.8670 | 0.9296 | 0.0000 | 0.0000 | 0.2064 | 0.0234 | 0.0440 | 0.0744 | 58.3872 | 100.0000 | 100.0000 | |
FTase Inhibitor I | Ftase | MAPK | 100.0000 | 100.0000 | 100.0000 | 0.7715 | 0.8851 | 0.9752 | 0.7468 | 0.8851 | 0.9752 | 0.0000 | 0.0000 | 0.0000 | 0.0099 | 0.0556 | 0.0941 | 100.0000 | 100.0000 | 100.0000 |